Is there a difference between tranexamic acid application routes in hip hemiarthroplasty?

Basit Öğe Kaydı
dc.contributor.authorDedeoğlu, Süleyman Semih
dc.contributor.authorÇabuk, Haluk
dc.contributor.authorYerli, Mustafa
dc.contributor.authorİmren, Yunus
dc.contributor.authorYüce, Ali
dc.contributor.authorBayraktar, Tahsin Olgun
dc.contributor.authorErkurt, Nazım
dc.date.accessioned2024-05-19T14:23:35Z
dc.date.available2024-05-19T14:23:35Z
dc.date.issued2022
dc.departmentİstinye Üniversitesien_US
dc.description.abstractObjectives: This study aimed to define the optimal efficacy route of tranexamic acid treatment given during hemiarthroplasty after femoral neck fracture. Methods: This study examined the files of patients with hip fractures over 65 years of age and treated surgically in our clinic between 2017 and 2019. Patients included in these files were grouped as non-tranexamic acid and topical and systemic tranexamic acid. Then, the demographic information, height and weight of the patient files, haemoglobin and hematocrit levels before and after the surgery, bleeding profiles, tranexamic acid dose and the route of administration, complications in postoperative follow-up, the amount of fluid coming from the drain and duration of drainage, postoperative intensive care follow-up duration of hospitalisation was investigated. Results: A total of 100 patients, 50 of whom were in the control group, 25 of whom were treated with topical tranexamic acid, and 25 of whom were treated with intravenous tranexamic acid, were included in this study. Postoperative blood transfusion was applied to 60% (n = 30) of the control group, 20% (n = 5) of the topical group, and 24% (n = 6) of the intravenous group. When compared statistically, it was found that topical and intravenous groups were lower than the control group (p = 0.001 and p = 0.002, respectively), but there was no significant difference between them (p = 0.759). When the blood loss calculations made by the Gross method were examined, the average of the control group was 1011.5 ml (179-1837 ml), the topical group was 695.7 ml (11-2503 ml), and the intravenous group was 710.9 ml (173-11315 ml) calculated as. When analysed statistically in terms of blood loss, it was found that the control group was significantly higher than the topical and intravenous groups, but there was no significant difference between the topical and intravenous groups (p = 0.002). Conclusions: Tranexamic acid applied to reduce blood loss during arthroplasty surgery can be used effectively either by topical or systemic methods.en_US
dc.identifier.doi10.18621/eurj.989590
dc.identifier.endpage566en_US
dc.identifier.issn2149-3189
dc.identifier.issue5en_US
dc.identifier.startpage560en_US
dc.identifier.trdizinid1150996en_US
dc.identifier.urihttps://doi.org/10.18621/eurj.989590
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/1150996
dc.identifier.urihttps://hdl.handle.net/20.500.12713/4040
dc.identifier.volume8en_US
dc.indekslendigikaynakTR-Dizinen_US
dc.language.isoenen_US
dc.relation.ispartofThe European Research Journalen_US
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmz20240519_kaen_US
dc.titleIs there a difference between tranexamic acid application routes in hip hemiarthroplasty?en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

TR-Dizin İndeksli Yayınlar Koleksiyonu